Open access, freely available online PLoS MEDICINE Persistent Amyloidosis following Suppression of Ab Production in a Transgenic Model of Alzheimer Disease
暂无分享,去创建一个
H. Lester | D. Borchelt | A. Savonenko | S. Younkin | L. Younkin | N. Jenkins | V. Gonzales | N. Copeland | J. Jankowsky | H. Slunt | J. Wen | Henry A Lester | Steven G Younkin | Nancy A Jenkins | Joanna L Jankowsky | Victoria Gonzales | David R Borchelt | Hilda H Slunt | Alena V Savonenko | Jason C Wen | Neal G Copeland | Linda H Younkin | Nancy A. Jenkins | Joanna L. Jankowsky | D. R. Borchelt | Alena V Savonenko | Jason C Wen | Neal G Copeland | Henry A Lester
[1] Rong Wang,et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.
[2] C. Holmes,et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.
[3] Andreas Weidemann,et al. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein , 1989, Cell.
[4] M. Citron. Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge. , 2004, Trends in pharmacological sciences.
[5] E. Check. Nerve inflammation halts trial for Alzheimer's drug , 2002, Nature.
[6] L. Mucke,et al. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice , 2001, Nature Medicine.
[7] D. Morgan,et al. Time-dependent reduction in Aβ levels after intracranial LPS administration in APP transgenic mice , 2004, Experimental Neurology.
[8] D. Borchelt,et al. Rapid detection of protein aggregates in the brains of Alzheimer patients and transgenic mouse models of amyloidosis. , 2002, Alzheimer disease and associated disorders.
[9] G. Higgins,et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. , 2004, The Journal of biological chemistry.
[10] A. Riggs,et al. Genomic sequencing. , 1993, Methods in molecular biology.
[11] K. Ashe,et al. Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.
[12] A. Hirano,et al. A COMPARATIVE STUDY OF MODIFIED BIELSCHOWSKY, BODIAN AND THIOFLAVIN S STAINS ON ALZHEIMER'S NEUROFIBRILLARY TANGLES , 1986, Neuropathology and applied neurobiology.
[13] Allan I. Levey,et al. Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo , 1996, Neuron.
[14] K. Henke,et al. Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease , 2003, Neuron.
[15] Marie Clark,et al. Where Can I Get More Information , 2006 .
[16] J. Wegiel,et al. The role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APPSW mice , 2001, Neurobiology of Aging.
[17] E. Kandel,et al. Control of Memory Formation Through Regulated Expression of a CaMKII Transgene , 1996, Science.
[18] R. Motter,et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.
[19] D. Selkoe,et al. Deciphering the genetic basis of Alzheimer's disease. , 2002, Annual review of genomics and human genetics.
[20] Brian J. Bacskai,et al. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy , 2001, Nature Medicine.
[21] W Brysch,et al. Ca2+/calmodulin protein kinase and protein kinase C expression during development of rat hippocampus. , 1993, Developmental neuroscience.
[22] J. Cumming,et al. Design and development of BACE-1 inhibitors. , 2004, Current opinion in drug discovery & development.
[23] Patrick L. McGeer,et al. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease , 2004, Experimental Neurology.
[24] S. Younkin,et al. Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain , 1995, The Journal of Biological Chemistry.
[25] David W. Smith,et al. Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor , 2005, Journal of Pharmacology and Experimental Therapeutics.
[26] Pritam Das,et al. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo , 2003 .
[27] S. Turner,et al. Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695* , 2001, The Journal of Biological Chemistry.
[28] Alexandra Flemming,et al. Infectious disease: Unravelling SARS lethality , 2005, Nature Reviews Drug Discovery.
[29] D. Wilcock,et al. Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice , 2001, Neurobiology of Aging.
[30] Joanna L. Jankowsky,et al. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase , 2004 .
[31] D. Coppola,et al. Microglial Activation and β-Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice , 2002, The Journal of Neuroscience.
[32] D. Borchelt,et al. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: Relationships to β-amyloid deposition and neurotransmitter abnormalities , 2005, Neurobiology of Disease.
[33] René Hen,et al. Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.
[34] G. Perry,et al. Identification and transport of full-length amyloid precursor proteins in rat peripheral nervous system , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[35] S. Younkin,et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.
[36] Koji Abe,et al. Amyloid cored plaques in Tg2576 transgenic mice are characterized by giant plaques, slightly activated microglia, and the lack of paired helical filament-typed, dystrophic neurites , 2002, Virchows Archiv.
[37] B. Hyman,et al. Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation , 2004, Nature Medicine.
[38] B. Hyman,et al. Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.
[39] B. Dubois,et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.
[40] S. Weggen,et al. Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity* , 2003, Journal of Biological Chemistry.
[41] Pritam Das,et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. , 2003, The Journal of clinical investigation.
[42] M. Wolfe. Therapeutic strategies for Alzheimer's disease , 2002, Nature Reviews Drug Discovery.
[43] D. Borchelt,et al. Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins , 1997, Neuron.
[44] M. Gossen,et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[45] D. Borchelt,et al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[46] B. Hyman,et al. Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy , 2002, The Journal of Neuroscience.
[47] M. Frotscher,et al. Cerebral Amyloid Induces Aberrant Axonal Sprouting and Ectopic Terminal Formation in Amyloid Precursor Protein Transgenic Mice , 1999, The Journal of Neuroscience.
[48] D. Wilcock,et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[49] M. Wolfe,et al. The Search for γ-Secretase and Development of Inhibitors , 2002 .
[50] D. Dickson,et al. Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/- Knock-Out Mice , 2003, The Journal of Neuroscience.
[51] T. Hökfelt,et al. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[52] M. Gossen,et al. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[53] Mikio Shoji,et al. Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.
[54] M. Citron,et al. Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease , 2003, The Journal of Neuroscience.
[55] David H. Cribbs,et al. Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.
[56] D L Price,et al. A vector for expressing foreign genes in the brains and hearts of transgenic mice. , 1996, Genetic analysis : biomolecular engineering.
[57] Patrick Tremblay,et al. Prion clearance in bigenic mice. , 2005, The Journal of general virology.
[58] M. Gossen,et al. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[59] D. Wilcock,et al. Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration , 2004, Neurobiology of Disease.
[60] Dave Morgan,et al. Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation , 2003, The Journal of Neuroscience.
[61] F. Gage,et al. Neprilysin Gene Transfer Reduces Human Amyloid Pathology in Transgenic Mice , 2003, The Journal of Neuroscience.
[62] Jay S. Fine,et al. Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation* , 2004, Journal of Biological Chemistry.
[63] S. Younkin,et al. Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.
[64] D. Wilcock,et al. Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition , 2004, The Journal of Neuroscience.
[65] C. van Broeckhoven,et al. Genetics of Early-Onset Alzheimer Dementia , 2003, TheScientificWorldJournal.
[66] J. Wegiel,et al. Cells of monocyte/microglial lineage are involved in both microvessel amyloidosis and fibrillar plaque formation in APPsw tg mice , 2004, Brain Research.
[67] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.